PURPOSE: Screening logs have the potential to help oncology clinical trial programs at the site level, as well as trial leaders, address enrollment in real time. Such an approach could be especially helpful in improving representation of racial/ethnic minority and other underrepresented populations in clinical trials. METHODS: The National Cancer Institute Community Cancer Centers Program (NCCCP) developed a screening log. Log data collected from March 2009 through May 2012 were analyzed for number of patients screened versus enrolled, including for demographic subgroups; screening methods; and enrollment barriers, including reasons for ineligibility and provider and patient reasons for declining to offer or participate in a trial. User feedback was obtained to better understand perceptions of log utility. RESULTS: Of 4,483 patients screened, 18.4% enrolled onto NCCCP log trials. Reasons for nonenrollment were ineligibility (51.6%), patient declined (25.8%), physician declined (15.6%), urgent need for treatment (6.6%), and trial suspension (0.4%). Major reasons for patients declining were no desire to participate in trials (43.2%) and preference for standard of care (39%). Major reasons for physicians declining to offer trials were preference for standard of care (53%) and concerns about tolerability (29.3%). Enrollment rates onto log trials did not differ between white and black (P = .15) or between Hispanic and non-Hispanic patients (P = .73). Other races had lower enrollment rates than whites and blacks. Sites valued the ready access to log data on enrollment barriers, with some sites changing practices to address those barriers. CONCLUSION: Use of screening logs to document enrollment barriers at the local level can facilitate development of strategies to enhance clinical trial accrual.
PURPOSE: Screening logs have the potential to help oncology clinical trial programs at the site level, as well as trial leaders, address enrollment in real time. Such an approach could be especially helpful in improving representation of racial/ethnic minority and other underrepresented populations in clinical trials. METHODS: The National Cancer Institute Community Cancer Centers Program (NCCCP) developed a screening log. Log data collected from March 2009 through May 2012 were analyzed for number of patients screened versus enrolled, including for demographic subgroups; screening methods; and enrollment barriers, including reasons for ineligibility and provider and patient reasons for declining to offer or participate in a trial. User feedback was obtained to better understand perceptions of log utility. RESULTS: Of 4,483 patients screened, 18.4% enrolled onto NCCCP log trials. Reasons for nonenrollment were ineligibility (51.6%), patient declined (25.8%), physician declined (15.6%), urgent need for treatment (6.6%), and trial suspension (0.4%). Major reasons for patients declining were no desire to participate in trials (43.2%) and preference for standard of care (39%). Major reasons for physicians declining to offer trials were preference for standard of care (53%) and concerns about tolerability (29.3%). Enrollment rates onto log trials did not differ between white and black (P = .15) or between Hispanic and non-Hispanic patients (P = .73). Other races had lower enrollment rates than whites and blacks. Sites valued the ready access to log data on enrollment barriers, with some sites changing practices to address those barriers. CONCLUSION: Use of screening logs to document enrollment barriers at the local level can facilitate development of strategies to enhance clinical trial accrual.
Authors: P N Lara; R Higdon; N Lim; K Kwan; M Tanaka; D H Lau; T Wun; J Welborn; F J Meyers; S Christensen; R O'Donnell; C Richman; S A Scudder; J Tuscano; D R Gandara; K S Lam Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: A Kaluzny; O Brawley; D Garson-Angert; J Shaw; P Godley; R Warnecke; L Ford Journal: J Natl Cancer Inst Date: 1993-12-01 Impact factor: 13.506
Authors: Andrea M Denicoff; Worta McCaskill-Stevens; Stephen S Grubbs; Suanna S Bruinooge; Robert L Comis; Peggy Devine; David M Dilts; Michelle E Duff; Jean G Ford; Steven Joffe; Lidia Schapira; Kevin P Weinfurt; Margo Michaels; Derek Raghavan; Ellen S Richmond; Robin Zon; Terrance L Albrecht; Michael A Bookman; Afshin Dowlati; Rebecca A Enos; Mona N Fouad; Marjorie Good; William J Hicks; Patrick J Loehrer; Alan P Lyss; Steven N Wolff; Debra M Wujcik; Neal J Meropol Journal: J Oncol Pract Date: 2013-10-15 Impact factor: 3.840
Authors: Eileen P Dimond; Robin T Zon; Bryan J Weiner; Diane St Germain; Andrea M Denicoff; Kandie Dempsey; Angela C Carrigan; Randall W Teal; Marjorie J Good; Worta McCaskill-Stevens; Stephen S Grubbs; Eileen P Dimond; Robin T Zon; Bryan J Weiner; Diane St Germain; Andrea M Denicoff; Kandie Dempsey; Angela C Carrigan; Randall W Teal; Marjorie J Good; Worta McCaskill-Stevens; Stephen S Grubbs Journal: J Oncol Pract Date: 2015-12-01 Impact factor: 3.840
Authors: Eudocia Q Lee; Ugonma N Chukwueke; Shawn L Hervey-Jumper; John F de Groot; Jose Pablo Leone; Terri S Armstrong; Susan M Chang; David Arons; Kathy Oliver; Kay Verble; Al Musella; Nicole Willmarth; Brian M Alexander; Amanda Bates; Lisa Doherty; Evanthia Galanis; Sarah Gaffey; Thomas Halkin; Bret E Friday; Maryam Fouladi; Nancy U Lin; David Macdonald; Minesh P Mehta; Marta Penas-Prado; Michael A Vogelbaum; Solmaz Sahebjam; David Sandak; Martin van den Bent; Michael Weller; David A Reardon; Patrick Y Wen Journal: Neuro Oncol Date: 2019-09-06 Impact factor: 12.300
Authors: Grace C Hillyer; Melissa Beauchemin; Dawn L Hershman; Moshe Kelsen; Frances L Brogan; Rossy Sandoval; Karen M Schmitt; Andria Reyes; Mary Beth Terry; Andrew B Lassman; Gary K Schwartz Journal: Clin Trials Date: 2020-02-03 Impact factor: 2.486
Authors: Herbert H Pang; Xiaofei Wang; Thomas E Stinchcombe; Melisa L Wong; Perry Cheng; Apar Kishor Ganti; Daniel J Sargent; Ying Zhang; Chen Hu; Sumithra J Mandrekar; Mary W Redman; Judith B Manola; Richard L Schilsky; Harvey J Cohen; Jeffrey D Bradley; Alex A Adjei; David Gandara; Suresh S Ramalingam; Everett E Vokes Journal: J Clin Oncol Date: 2016-09-30 Impact factor: 44.544
Authors: Winson Y Cheung; Lindsay A Renfro; David Kerr; Aimery de Gramont; Leonard B Saltz; Axel Grothey; Steven R Alberts; Thierry Andre; Katherine A Guthrie; Roberto Labianca; Guido Francini; Jean-Francois Seitz; Chris O'Callaghan; Chris Twelves; Eric Van Cutsem; Daniel G Haller; Greg Yothers; Daniel J Sargent Journal: J Clin Oncol Date: 2016-02-08 Impact factor: 44.544
Authors: Aisha T Langford; Ken Resnicow; Eileen P Dimond; Andrea M Denicoff; Diane St Germain; Worta McCaskill-Stevens; Rebecca A Enos; Angela Carrigan; Kathy Wilkinson; Ronald S Go Journal: Cancer Date: 2013-12-10 Impact factor: 6.860
Authors: Eileen P Dimond; Diane St Germain; Lianne M Nacpil; Howard A Zaren; Sandra M Swanson; Christopher Minnick; Angela Carrigan; Andrea M Denicoff; Kathleen E Igo; Jared D Acoba; Maria M Gonzalez; Worta McCaskill-Stevens Journal: Clin Trials Date: 2015-02-17 Impact factor: 2.486